Loading
A phase 1/2 trial of TCC1727 tablet 90mg in non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, endometrial cancer and melanoma, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07371663 by Beijing Tide Pharmaceutical Co., Ltd, with 266 participants planned, started 2025-12-03 and due to reach its primary completion in 2028-09-30. Interventions recorded: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg and benmelstobart Injection.
Shares Beijing Tide Pharmaceutical and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Melanoma and the tag pipeline.
Shares Endometrial cancer, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.